Twist Bioscience Corp (TWST): Total Liabilities
$168.90M
As of 2025-09-30
$226.70M
As of 2026-06-30
-0.6%
3-year compound annual growth
+22.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $168.90M | +19.3% | 2025-11-17, Balance as of period end |
| 2024-09-30 | $141.63M | -7.4% | 2025-11-17, Balance as of period end |
| 2023-09-30 | $152.97M | -11.1% | 2024-11-18, Balance as of period end |
| 2022-09-30 | $171.99M | +41.8% | 2023-11-21, Balance as of period end |
| 2021-09-30 | $121.28M | +93.7% | 2023-06-05, Balance as of period end |
| 2020-09-30 | $62.62M | +79.4% | 2021-11-23, Balance as of period end |
| 2019-09-30 | $34.91M | +30.6% | 2020-11-27, Balance as of period end |
| 2018-09-30 | $26.73M | n/a | 2019-12-13, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
Compare TWST, KRYS, IMCR, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗